Sign In
Buy KTRA
$0.215
+0 (+0%)
At Close: Jan 16, 2025
Wall Street starts in the red
11:38am, Monday, 12'th Apr 2021
10.15am: Proactive North America headlines: Genprex Inc (NASDAQ:GNPX) presents positive preclinical data for lung cancer drug REQORSA at American Association for Cancer Research meeting Kintara Ther
Kintara Taking The Lead In Developing New And Innovative Rare Cancer Therapies
10:51am, Monday, 05'th Apr 2021
Kintara Therapeutics, Inc. Chief Executive Officer Saiid Zarrabian participated in the Benzinga Biotech Small Cap Conference held March 24-25, 2021. Kintara Therapeutics, Inc. (NASDAQ: KTRA) a bioph
Kintara Therapeutics appoints Dr Mario Lacouture to its scientific advisory board for cutaneous metastatic breast cancer
09:31am, Wednesday, 03'rd Mar 2021
Kintara Therapeutics Inc (NASDAQ:KTRA) (FRA:3DM) has hired cancer expert Dr Mario Lacouture to its Cutaneous Metastatic Breast Cancer (CMBC)-focused scientific advisory board. It comes as the compan
Kintara Therapeutics Concludes Enrollment In Recurrent Arm Of VAL-083 Mid-Stage Brain Cancer Study
12:56pm, Wednesday, 17'th Feb 2021
Kintara Therapeutics Inc (NASDAQ: KTRA) has enrolled the final patient in the recurrent arm of its ongoing Phase 2 study evaluating VAL-083 for glioblastoma multiforme, the most aggressive form of
Kintara Therapeutics enrolls last patient in Phase 2 VAL-083 trial for recurrent glioblastoma multiforme
10:35am, Wednesday, 17'th Feb 2021
Kintara Therapeutics Inc (NASDAQ:KTRA) announced Wednesday that it has enrolled the final patient in the recurrent arm of its ongoing Phase 2 clinical glioblastoma multiforme (GBM) study of its VAL-08
Kintara Therapeutics says it has enough cash to fund its planned operations into the fourth quarter of calendar 2021
10:12am, Friday, 12'th Feb 2021
Kintara Therapeutics Inc (NASDAQ:KTRA), the cancer-focused biopharma, said it has enough cash to fund its planned operations into the fourth quarter of calendar 2021, as the company posted its second-
Why Kintara Therapeutics's Stock is Down During Today's Session
09:53am, Friday, 12'th Feb 2021
Kintara Therapeutics (NASDAQ:KTRA) is currently down 7.64% to a price of $2.46. The stock's volume is currently 77.04 thousand, which is roughly 4.66% of its recent 30-day volume average of 1.66 milli
Kintara Therapeutics Announces First Fiscal Quarter 2021 Financial Results and Recent Corporate Updates
08:00am, Friday, 13'th Nov 2020
SAN DIEGO, Nov. 13, 2020 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therap
Kintara Therapeutics (KTRA) Investor Presentation - Slideshow
01:34pm, Friday, 04'th Sep 2020
The following slide deck was published by Kintara Therapeutics, Inc. in conjunction with this event..
